Sarepta Therapeutics (SRPT) Cost of Revenue (2017 - 2026)

Sarepta Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $108.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 20.93% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $810.8 million (up 99.66% YoY), while the FY2025 annual figure was $839.6 million, up 163.12% from the prior year.
• Cost of Revenue for Q1 2026 stood at $108.8 million, down from $398.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $398.7 million in Q4 2025, with the low at $30.8 million in Q4 2022.
• The 5-year median for Cost of Revenue is $44.5 million (2024), against an average of $91.6 million.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue soared 242.48% in 2025, then slipped 20.93% in 2026.
• Sarepta Therapeutics' Cost of Revenue stood at $30.8 million in 2022, then surged by 43.43% to $44.2 million in 2023, then surged by 199.49% to $132.3 million in 2024, then soared by 201.36% to $398.7 million in 2025, then slumped by 72.72% to $108.8 million in 2026.
• Business Quant data shows SRPT's Cost of Revenue at $108.8 million in Q1 2026, $398.7 million in Q4 2025, and $150.8 million in Q3 2025.